Skip to main content

Expect More Biotech Consolidation Activity in 2022

The biotechnology industry is often a hotbed of mergers and acquisitions speculation. Announced deals are a different matter altogether. This year’s pace of biotechnology deal-making was decent, and with many blue-chip pharmaceuticals and mature biotechnology companies armed with massive...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.